This meta-analysis demonstrated that PD-1/PD-L1 inhibitors were significantly associated with a 35% reduction in the risk of progression or death compared with chemotherapy for advanced lung cancer with BMs. This evidence concerns the gene PDCD1 and lung carcinoma.